Christopher Bredeson
Overview
Explore the profile of Christopher Bredeson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
2766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dhir V, Prince C, Allan D, Atkins H, Bredeson C, Kekre N, et al.
Eur J Haematol
. 2025 Jan;
PMID: 39757868
Background: Dose adjustments of Day 11 Methotrexate (MTx) for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation (HCT) are common due to mucositis, renal injury, or other reasons. The impact...
2.
Hickey C, Zhang M, Allbee-Johnson M, Romee R, Majhail N, Al Malki M, et al.
Transplant Cell Ther
. 2025 Jan;
31(3):174.e1-174.e12.
PMID: 39755256
Background: Post-transplant cyclophosphamide (PTCy) is a commonly used graft-vs-host disease (GVHD) prophylaxis, particularly in the setting of haploidentical (haplo) hematopoietic cell transplantation (HCT). The rate of graft failure has been...
3.
Beland B, Storek J, Quartermain L, Hahn C, Pringle C, Bourque P, et al.
Ann Clin Transl Neurol
. 2024 Dec;
12(1):56-68.
PMID: 39737848
Objectives: Patients with refractory myasthenia gravis (MG) have few treatment options. Autologous hematopoietic stem cell transplantation (HSCT) has been used to treat immune diseases; however, its use in the treatment...
4.
Tan X, Maltez M, Mallick R, Hamelin L, McDiarmid S, Cieniak C, et al.
Eur J Haematol
. 2024 Oct;
114(2):276-284.
PMID: 39445482
Background: Chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated remarkable efficacy in relapsed or refractory large B cell lymphoma, but real-world evidence is needed to confirm safety and efficacy when...
5.
Verville L, McKay C, Kouroukis T, Apostolovski S, Sabloff M, Buckstein R, et al.
Curr Oncol
. 2024 Aug;
31(8):4656-4674.
PMID: 39195330
Acute leukemia is a rapidly progressive cancer of the blood and bone marrow that requires a high degree of complex, specialized, resource-intensive clinical and supportive care. The aging Canadian population...
6.
Dandoy C, Adams J, Artz A, Bredeson C, Dahi P, Dodd T, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):942-954.
PMID: 39067790
Immune effector cell (IEC) therapy represents a transformative advancement in oncology, leveraging the immune system to combat various malignancies. This article outlines a comprehensive framework for establishing and maintaining quality...
7.
Chalchal H, Dhir V, Masurekar A, Atkins H, Bredeson C, Kennah M, et al.
Eur J Haematol
. 2024 Jul;
113(4):543-549.
PMID: 38979885
Background: Anti-thymocyte globulin (ATG) based graft versus host disease (GVHD) prophylaxis is widely used for mismatched unrelated donor allogeneic hematopoietic cell transplantation (HCT) although optimal dose remains unclear. Although recent...
8.
Jain T, Estrada-Merly N, Salas M, Kim S, DeVos J, Chen M, et al.
Blood Adv
. 2024 Jun;
8(16):4281-4293.
PMID: 38916866
We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs...
9.
Abid M, Estrada-Merly N, Zhang M, Chen K, Bredeson C, Allan D, et al.
Transplant Cell Ther
. 2023 Jul;
29(10):611-618.
PMID: 37481243
Although allogeneic hematopoietic cell transplantation (alloHCT) offers cure for older patients with acute lymphoblastic leukemia (ALL), disease relapse remains a major issue. Whether matched sibling donors (MSDs) are still the...
10.
Abid M, Estrada-Merly N, Zhang M, Chen K, Allan D, Bredeson C, et al.
Transplant Cell Ther
. 2023 Jul;
29(9):578.e1-578.e9.
PMID: 37406882
Allogeneic hematopoietic cell transplantation (alloHCT) provides cure for older patients with acute myeloid leukemia (AML); however, disease relapse remains a major concern. Based on recent data suggesting that younger donor...